Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment

NCT ID: NCT03585777

Last Updated: 2018-07-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-11

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Klotho is a protein found in serum, kidney,heart,brain and in other tissues,it has many functions,it is viewed as the anti aging hormone. Aging kidneys are characterized by progressive scarring and measurable declines in renal function

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives To study serum klotho level among diabetic patients attending diabetes and endocrine clinic in Fayoum university on oral antidiabetic treatment

Study Design:

This study will be an observational prospective cohort study. The study duration will be 2 months.

Study Methods:

* Population of Study
* Group 1 :compare serum klotho levels in patients taking glimeperirde versus levels in patients taking metformin
* Group 2 : compare serum klotho levels in patients taking glimeperirde versus levels in patients taking linagliptin
* Group 3 : compare serum klotho levels in patients taking glimeperirde versus levels in patients taking impaglifluzin
* Inclusion Criteria :
* Group 1 :Diabetics candidate for oral treatment
* Group 2 :Diabetics candidate for oral treatment
* Group 3 :Diabetics candidate for oral treatment
* Exclusion Criteria :

Diabetics candidate for insulin treatment

There will be three arms to this study; the first arm will enroll patients on glimepiride and patients on metformin to compare serum klotho levels. The second arm will enroll patients on glimepiride and patients on linagliptin to compare serum klotho levels. The third arm will enroll patients on glimepiride and patients on impaglifluzin to compare serum klotho levels Each arm will enroll 40 patients, 20 patients on glimiperide treatment,20 patient will on the other drug,patients will be selected from Fayoum university diabetes and endocrine clinic

Data collection:

Patients will be subjected to; full clinical examination,waist hip ratio assessment,BMI assessment fasting blood glucose,2PP blood glucose,HbA1C, urea, creatinine, uric acid total calcium,albumin, phospherus, estimated GFR, ACR, total cholesterol, triglycerides, serum klotho, FGF 23 levels assessment , also fracrtional excretion of phospherus will be assessed. Control of blood glucose will be done along the period of the study. At the end of the 2 months,reassessment of the above mentioned parameters will be done.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin

No interventions assigned to this group

Group 2

Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin

No interventions assigned to this group

Group 3

Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetics candidate for oral treatment

Exclusion Criteria

* Diabetics candidate for insulin treatment
Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fayoum University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Abdelkawi Hammad

Lecturer of internal medicine,faculty of medicine,Fayoum university

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fayoum university Hospital

Al Fayyum, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ahmed Hammad, MD

Role: CONTACT

00201001574639

Mohammed Mashaheet, MD

Role: CONTACT

00201227904660

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ahmed Hammad, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VCG 3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nitric Oxide (NO) Activity and Diabetic Nephropathy
NCT00136188 COMPLETED PHASE2/PHASE3
PK and PD of YG1699 in CKD Patients With Diabetes
NCT06648876 NOT_YET_RECRUITING PHASE1
OPTIMISE-CKD Drug Utilization
NCT05932901 COMPLETED